Phase II Study of Carfilzomib, Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma


Phase II Study of Carfilzomib, Cyclophosphamide and Dexamethasone for Newly Diagnosed Multiple Myeloma
Slides from a presentation at EHA 2013 and transcribed comments from a recent interview with Antonio Palumbo, MD (8/20/13)
Bringhen S et al. Carfilzomib, cyclophosphamide and dexamethasone (CCd) for newly diagnosed multiple myeloma (MM) patients: Initial results of a multicenter, open label Phase II study. Proc EHA 2013;Abstract S578.

Dr Palumbo is Chief of the Myeloma Unit in the University of Torino’s Division of Hematology in Torino, Italy.